Age at onset (year)
Birth year
Neonatal BCG vaccination program
BCG administered in school children if TST negative
Clinical syndromes associated with COVID-19
Clinical syndromes associated with COVID-19
Clinical syndromes associated with COVID-19
Clinical syndromes associated with COVID-19
Clinical syndromes associated with COVID-19
Total cases
Rate per million (Population)
Asymptomatic Mild illness Pneumonia Severe pneumonia ARDS
Children (<18) Children (<18) Children (<18) Children (<18) Children (<18) Children (<18) Children (<18) Children (<18) Children (<18) Children (<18) Children (<18)
4–17 2002–2016 Vaccinated with Tokyo-172 strain No 1 5 3 0 0 9 3.1
(11.1%) (55.6%) (33.3%) (2,942,611)
Adults (≥18) Adults (≥18) Adults (≥18) Adults (≥18) Adults (≥18) Adults (≥18) Adults (≥18) Adults (≥18) Adults (≥18) Adults (≥18) Adults (≥18)
18–24 1995–2002 Vaccinated with Tokyo-172 strain No 12 86 16 3 0 117 56.3
(10.3%) (73.5%) (13.7%) (2.6%) (2,076,390)
25–33 1986–1995 Vaccinated with Tokyo-172 strain No 9 84 15 1 0 109 38.1
(8.3%) (77.1%) (13.8%) (0.9%) (2,864,075)
34–41 1978–1986 Vaccinated with Tokyo-172 strain Yes 1 36 8 0 0 45 14.4
(2.2%) (80.0%) (17.8%) (3,122,489)
42–54 1965–1978 Vaccinated with Pasteur-1173 P2 strain Yes 4 18 22 1 6 51 10.7
(7.8%) (35.3%) (43.1%) (2.0%) (11.8%) (4,745,729)
≥ 55 Before 1965 Not implemented Yes 6 27 27 14 11 85 12.0
(7.1%) (31.8%) (31.8%) (16.5%) (12.9%) (7,092,231)
Total
33
256
91
19
17
416
18.2 (22,843,525)